Artificial intelligence (AI) helps a Sarasota, Florida, health system catch lung nodules that appear on CT scans for patients treated for scores of conditions, allowing them to be referred for a possible lung cancer diagnosis.

Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) representing the most prevalent subtypes of non-small cell lung cancer (NSCLC).

Discover protective tips to lower lung cancer risk even with a smoking history. Proven approaches for current and former smokers to strengthen lung health.

The study authors say their findings argue for careful reading of CT scans done for other reasons that may reveal the presence of lung nodules.

The Queen's Health Systems in Hawaii has opened the Queen's Advanced Lung Institute, a facility on Hawai'i for the diagnosis and treatment of lung cancer. Featuring a multi-disciplinary team and current technology,

Cancer is a complex condition marked by the uncontrolled growth of cells in the body. When this process begins in the lungs, it’s referred to as lung cancer, and it has the potential to extend its reach to other organs.

Colonoscopies, mammograms, Pap smears and prostate exams are designed to detect early signs of cancer. Local health care officials want to raise the profile of a fifth cancer-detection test that's

As an expert explained in an interview with CURE, we may be in the midst of a “new era” for small cell lung cancer research. This optimism comes in the wake of the Food and Drug Administration’s (FDA’s) approval of Imdelltra (tarlatamab-dlle) in May 2024 for the treatment of patients with extensive-stage small cell lung cancer (SCLC).

The Queen’s Advanced Lung Institute will feature a team of expert health care providers focused on providing high quality care and early diagnosis of lung cancer for patients.

Utah has the lowest rate of smoking in the nation, but lung cancer is the leading cause of cancer death in the state, according to the EPA.

The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in different provinces and territories will cover the drug's cost for patients, according to a news release by Regeneron Canada.